Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 2/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 14/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17091637 | 0.88 | CYP11B2 (0.43) | SLC22A12ARPGRPRKCQCYP11B2 | |
| SCHEMBL14225086 | 0.87 | SLC22A12 (0.50) | SLC22A12ARCYP11B2CYP11B1 | |
| SCHEMBL14239302 | 0.86 | AR (0.49) | SLC22A12ARPGRPRKCQCYP11B2 | |
| SCHEMBL14225092 | 0.84 | CYP11B2 (0.45) | SLC22A12PRKCQCYP11B2CYP11B1 | |
| SCHEMBL1769849 | 0.79 | SLC22A12 (0.56) | SLC22A12ARPGRPRKCQCYP11B2 | |
| SCHEMBL14152211 | 0.76 | CYP11B2 (0.50) | SLC22A12CYP11B2CYP11B1 | |
| SCHEMBL1769864 | 0.74 | SLC22A12 (0.54) | SLC22A12ARPGRPRKCQCYP11B2 | |
| SCHEMBL27892917 | 0.72 | CYP11B2 (0.38) | PRKCQCYP11B2CYP11B1 | |
| SCHEMBL2975824 | 0.71 | PRKCQ (0.65) | PRKCQ | |
| SCHEMBL1769875 | 0.70 | CYP11B2 (0.51) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501678-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | claimed |
| EP-2501678-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-8519134-B2 | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| WO-2011061168-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | SLC22A12 2415/4885AR 123/4885PGR 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.